UBC experts on new Omicron-specific vaccine
Health Canada has approved a vaccine by Moderna that specifically targets the Omicron variant of SARS-CoV-2. UBC experts are available to comment.
Sep 1, 2022
Futuristic coating for hospital fabrics and activewear kills COVID and E. coli
UBC researchers have developed an inexpensive, non-toxic coating for almost any fabric that decreases the infectivity of the virus that causes COVID-19 by up to 90 per cent.
Feb 10, 2022
UBC clinical trial supports new self-administered rapid antigen test
Thanks to new research compiled with data from UBC’s first on-campus clinical study, a new self-administered rapid antigen test will soon be available in Canada. It’s a tool that could help combat growing uncertainty, prevent transmission and potentially save lives.
Dec 23, 2021
UBC experts on new SARS-CoV-2 variant ‘Omicron’
A heavily mutated variant of the SARS-CoV-2 virus—designated “Omicron”—has emerged, with early cases concentrated primarily in South Africa. UBC experts are available to comment.
Nov 26, 2021
UBC research shows wastewater genomic testing can effectively track COVID-19 variants of concern within a region
Wastewater testing can accurately and rapidly identify levels of COVID-19 infections in the community, including the rise of variants of concern, suggests new research led by UBC professor Dr. Ryan Ziels.
Jul 12, 2021
Canadian researchers lead development and testing of promising treatment for COVID-19 variants
A new anti-viral drug could improve COVID-19 outcomes and survival rates — and is highly effective against multiple variants — according to a new study led by researchers at the University of British Columbia and Université de Sherbrooke.
May 11, 2021
UBC researchers unveil first molecular images of B.1.1.7 COVID-19 mutation
UBC researchers are the first in the world to publish structural images of the N501Y mutation on the SARS-CoV-2 spike protein—a change believed to be partly responsible for the highly infectious nature and rapid spread of variant B.1.1.7.
May 3, 2021
Potential ‘Achilles’ heel’ of SARS-CoV-2 virus captured on video
Proteins known as lectins can bind to the spike protein on the SARS-CoV-2 virus and prevent it from accessing human cells, an international team of researchers led by the University of British Columbia’s Dr. Josef Penninger has demonstrated.
Apr 30, 2021
Cloud computing support accelerates COVID-19 vaccine improvements
For the last 11 months, UBC biochemistry and molecular biology professor Prof.. Leonard Foster (he/him/his) and his team have been studying how SARS-CoV-2 – the virus responsible for COVID-19 – attacks the human body, in hopes of developing a more targeted vaccine with fewer side effects.
Apr 14, 2021
Trial drug can significantly block early stages of COVID-19 in engineered human tissues
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.
Apr 2, 2020
Pilot clinical trial in China to test UBC researcher’s findings as a targeted therapy for COVID-19
A University of British Columbia researcher is part of an international team working with a biotechnology company on a pilot clinical trial of a potential new treatment for patients with severe coronavirus infections in China.
Feb 25, 2020